RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: Its application as a therapeutic agent

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 853-861

  Park, Mi Young ^a   Park, Yoon Shin ^b   Nam, Jae Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cell proliferation protein; Granulin epithelin precursor; HCC; shRNA; siRNA

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; CYCLIN D1; GENE PRODUCT; GRANULIN EPITHELIN PRECURSOR; GROWTH FACTOR; PROTEIN GEP; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE; GEP GENE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; TIME; TUMOR REGRESSION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL GROWTH PROCESSES; CYCLIN D1; DOWN-REGULATION; G2 PHASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUBULIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960885570     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1095     Document Type: Article

References (31)

1. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M and Venook A: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005, 2010.
2. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
3. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Eng J Med 340: 745-750, 1999. (Pubitemid 29114292)
4. Benvegnù L, Gios M, Boccato S and Alberti A: Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53: 744-749, 2004. (Pubitemid 38561455)
5. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A and Colombo M: The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43: 1303-1310, 2006. (Pubitemid 43980109)
6. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
7. Cabrera R and Nelson DR: The management of hepatocellular carcinoma. Aliment Pharmacol Ther 31: 461-476, 2010.
8. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
9. Castello G, Costantini S and Scala S: Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 8: 109-119, 2010.
10. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, van de Rijn M, Botstein D and Brown PO: Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939, 2002. (Pubitemid 34651483)
11. Creppy EE, Traoré A, Baudrimont I, Cascante M and Carratú MR: Recent advances in the study of epigenetic effects induced by the phycotoxin okadaic acid. Toxicology 181-182: 43-47, 2002.
12. Shoyab M, McDonald VL, Byles C, Todaro GJ and Plowman GD: Epithelins 1 and 2: isolation and characterization of two cysteinerich growth-modulating proteins. Proc Natl Acad Sci USA 87: 7912-7916, 1990.
13. Hrabal R, Chen Z, James S, Bennett HP and Ni F: The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol 3: 747-752, 1996.
14. He Z, Ong CH, Halper J and Bateman A: Progranulin is a mediator of the wound response. Nat Med 9: 225-229, 2003. (Pubitemid 36227726)
15. Cheung ST, Wong SY, Leung KL, Chen X, So S, Ng IO and Fan ST: Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 10: 7629-7636, 2004. (Pubitemid 39557526)
16. Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY and Fan ST: Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47: 1524-1532, 2008. (Pubitemid 351702736)
17. Huang C, Li M, Chen C and Yao Q: Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 12: 637-645, 2008. (Pubitemid 351699481)
18. Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433, 2009.
19. Yan X, Chua MS, He J and So SK: Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer 7: 19-27, 2008.
20. Fu Y, Huang J, Wang KS, Zhang X and Han ZG: RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells. Mol Biol Rep 38: 693-702, 2011.
21. Fernández M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol 50: 604-620, 2009.
22. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S and Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998, 2008.
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
24. Bergé M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre JS, Lévy BI, Tucker GC, Tobelem G and Merkulova-Rainon T: Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 177: 3192-3201, 2010.
25. Yau T, Chan P, Epstein R and Poon RT: Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 14: 6437-6441, 2008.
26. Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, Liu H and Xiao H: In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol 108: 177-184, 2011.
27. Yoshinari K, Miyagishi M and Taira K: Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 32: 691-699, 2004. (Pubitemid 38263060)
28. Rusan NM, Fagerstrom CJ, Yvon AM and Wadsworth P: Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol Biol Cell 12: 971-980, 2001. (Pubitemid 33051992)
29. Guo WH, Yuan LH, Xiao ZH, Liu D and Zhang JX: Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma. J Cancer Res Clin Oncol 137: 533-541, 2011.
30. Witzel II, Koh LF and Perkins ND: Regulation of cyclin D1 gene expression. Biochem Soc Trans 38: 217-222, 2010.
31. Hirohashi S, Bulm HE, Ishak KG, et al: Hepatocellular carcinoma. In: World Health Organization Classification of Tumors. Pathology and Genetics Tumors of the Digestive System. Hamilton SR and Aaltonen LA (eds). World Health Organization, Geneva, pp158-172, 2000.